**Question:** Therapeutic drug development which is the newest agent -

A. New chemical entity
B. Biosimilar
C. Repurposing
D. Gene therapy

**Core Concept:**

The field of therapeutic drug development encompasses various strategies for creating, enhancing, and optimizing medications to treat various medical conditions. The newest agent among the given options refers to a relatively recent innovation in this field.

**Why the Correct Answer is Right:**

Option D, Gene therapy, is the newest agent in therapeutic drug development. Gene therapy involves modifying an individual's genetic material to treat or prevent disease. It is a relatively new approach compared to the other options, which have been more established in drug development.

**Why Each Wrong Option is Incorrect:**

A. New chemical entity (NCE) is a term used to describe a drug molecule that has never been approved for human use before. However, NCEs have been around for a long time and are not the newest agent compared to gene therapy.

B. Biosimilars are similar biological products that are highly similar to, but not identical to, a reference product. Although biosimilars have become increasingly important in recent years, they are not the newest agent compared to gene therapy.

C. Repurposing involves discovering new uses for existing drugs, either approved or investigational. While repurposing is a valuable strategy in drug development, it has been around for a longer period than gene therapy.

**Clinical Pearl / High-Yield Fact:**

Gene therapy represents a groundbreaking innovation in drug development, offering potential treatments for genetic disorders and various diseases by modifying an individual's genetic material. As a relatively new approach, gene therapy has the potential to revolutionize the field and significantly impact patient care in the future.